Human Genome Epidemiology Literature Finder
Records 1 - 28 (of 28 Records) |
Query Trace: Diarrhea and ABCG2[original query] |
---|
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute 2006 Dec 98 (23): 1739-42. Cusatis George, Gregorc Vanesa, Li Jing, Spreafico Anna, Ingersoll Roxann G, Verweij Jaap, Ludovini Vienna, Villa Eugenio, Hidalgo Manuel, Sparreboom Alex, Baker Sharyn |
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007 Jul 110 (1): 138-47. Han Ji-Youn, Lim Hyeong-Seok, Yoo Yeon-Kyeong, Shin Eun Soon, Park Yong Hoon, Lee Sung Young, Lee Jong-Eun, Lee Dea Ho, Kim Heung Tae, Lee Jin S |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. Cancer science 2008 Dec 99 (12): 2496-501. Kim In-Suk, Kim Hoon-Gu, Kim Dong Chul, Eom Hyeon-Seok, Kong Sun-Young, Shin Ho-Jin, Hwang Sang-Hyun, Lee Eun-Yup, Lee Gyeong-W |
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. Journal of human genetics 2009 Oct 54 (10): 572-80. Cha Pei-Chieng, Mushiroda Taisei, Zembutsu Hitoshi, Harada Hiromasa, Shinoda Noriyuki, Kawamoto Shunji, Shimoyama Rai, Nishidate Toshihiko, Furuhata Tomohisa, Sasaki Kazuaki, Hirata Koichi, Nakamura Yusu |
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer chemotherapy and pharmacology 2010 Sep 66 (4): 691-8. Akasaka Keiichi, Kaburagi Takayuki, Yasuda Shin'ichi, Ohmori Kyoko, Abe Kaori, Sagara Hironori, Ueda Yoshihiko, Nagao Koshu, Imura Johji, Imai Yas |
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011 Feb 12 (2): 159-70. Lemos Clara, Giovannetti Elisa, Zucali Paolo A, Assaraf Yehuda G, Scheffer George L, van der Straaten Tahar, D'Incecco Armida, Falcone Alfredo, Guchelaar Henk-Jan, Danesi Romano, Santoro Armando, Giaccone Giuseppe, Tibaldi Carmelo, Peters Godefridus |
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PloS one 2012 7 (8): e42875. Boudou-Rouquette Pascaline, Narjoz Céline, Golmard Jean Louis, Thomas-Schoemann Audrey, Mir Olivier, Taieb Fabrice, Durand Jean-Philippe, Coriat Romain, Dauphin Alain, Vidal Michel, Tod Michel, Loriot Marie-Anne, Goldwasser François, Blanchet Beno |
Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis research & therapy 2012 14 (4): R163. Wiese Michael D, Schnabl Matthew, O'Doherty Catherine, Spargo Llewellyn D, Sorich Michael J, Cleland Leslie G, Proudman Susanna |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya journal of medical science 2012 Feb 74 (1-2): 133-40. Tamura Mariko, Kondo Masashi, Horio Mihoko, Ando Maki, Saito Hiroshi, Yamamoto Masashi, Horio Yoshitsugu, Hasegawa Yoshino |
[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2013 Jun 16 (6): 524-8. Sun Zhi-wei, Wang Xi-cheng, Gao Jing, Li Jie, Li Yan-yan, Dang Yun-zhi, Shen L |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clinical pharmacokinetics 2013 Jul 52 (7): 593-609. Fukudo Masahide, Ikemi Yasuaki, Togashi Yosuke, Masago Katsuhiro, Kim Young Hak, Mio Tadashi, Terada Tomohiro, Teramukai Satoshi, Mishima Michiaki, Inui Ken-Ichi, Katsura Toshi |
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and genomics 2015 Sep . Chen Sylvia, Villeneuve Lyne, Jonker Derek, Couture Félix, Laverdière Isabelle, Cecchin Erica, Innocenti Federico, Toffoli Giuseppe, Lévesque Eric, Guillemette Chant |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics 2016 09 17 (14): 1483-90. Bins Sander, Lenting Anne, El Bouazzaoui Samira, van Doorn Leni, Oomen-de Hoop Esther, Eskens Ferry Alm, van Schaik Ron Hn, Mathijssen Ron |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget 2017 Aug 8 (34): 57528-57536. Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori 2018 12 106 (2): 87-94. Paulík Adam, Nekvindová Jana, Filip Stanisl |
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer chemotherapy and pharmacology 2019 Aug . Reddick Samuel J, Campagne Olivia, Huang Jie, Onar-Thomas Arzu, Broniscer Alberto, Gajjar Amar, Stewart Clinton |
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2019 7 134 1-6. Hayashi Hideki, Iihara Hirotoshi, Hirose Chiemi, Fukuda Yoshihisa, Kitahora Mika, Kaito Daizo, Yanase Komei, Endo Junki, Ohno Yasushi, Suzuki Akio, Sugiyama Tadas |
A meta-analysis of ABCG2 gene polymorphism and non-small cell lung cancer outcomes. Genetics and molecular biology 2020 3 42 (4): e20180234. Fu Lei, Wang Rong, Yin Ling, Shang Xiaopu, Zhang Runtong, Zhang Pengj |
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Investigational new drugs 2022 9 40 (6): 1254-1262. Yokota Hayato, Sato Kazuhiro, Sakamoto Sho, Okuda Yuji, Fukuda Natsuki, Asano Mariko, Takeda Masahide, Nakayama Katsutoshi, Miura Masato |
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy. Journal of biochemical and molecular toxicology 2022 12 e23269. Sharma Parul, Singh Navneet, Sharma Siddhar |
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC pulmonary medicine 2022 11 22 (1): 454. Nio Yuta, Ishida Hiroo, Matsumoto Natsumi, Kusumoto Sojiro, Kubota Yutaro, Tsunoda Takuya, Sasaki Yasutsuna, Fujita Ken-Ic |
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer. International journal of molecular sciences 2023 3 24 (6): . Cantara Silvia, Dalmiglio Cristina, Marzocchi Carlotta, Sagnella Alfonso, Brilli Lucia, Trimarchi Andrea, Maino Fabio, Valerio Laura, Castagna Maria Graz |
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 2023 1 . Ishikawa Emi, Yokoyama Yuta, Chishima Haruna, Kasai Hidefumi, Kuniyoshi Ouki, Kimura Motonori, Hakamata Jun, Nakada Hideo, Suehiro Naoya, Nakaya Naoki, Nakajima Hideo, Ikemura Shinnosuke, Kawada Ichiro, Yasuda Hiroyuki, Terai Hideki, Jibiki Aya, Kawazoe Hitoshi, Soejima Kenzo, Muramatsu Hiroshi, Suzuki Sayo, Nakamura Tomono |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: